207_Combined course Presentations

Relevant Questions:

 Molecular evolution of resistance to treatment:  acquired during therapy? 

Already present in a clonal subpopulation within the tumours prior to the initiation of therapy?

 Is resistance is therefore a fait accompli—the time to recurrence is simply the interval required for the subclone to repopulate the lesion.?  Is the short time interval of recurrence due to the rapid expansion of the resistant subclone immediately following treatment initiation?

 Required: Combination therapies targeting at least two different pathways - processes.